ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,894.34
0.02%
Gold vs US Dollar
2,304.83
-3.03%
Brent Oil
79.645
-0.29%
Bitcoin
69,154.53
-2.27%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. 4D Molecular Therapeutics Inc (FDMT)

  7. 4D Molecular Therapeutics Inc (FDMT) News

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FDMT
DateTimeSourceHeadlineSymbolCompany
06/06/202412:30GlobeNewswire Inc.4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
04/06/202413:00GlobeNewswire Inc.4DMT Announces Presentations at Clinical Trials at the Summit 2024 MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
03/06/202413:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
30/05/202413:00GlobeNewswire Inc.4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202421:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202400:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202400:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
21/05/202401:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
09/05/202421:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
09/05/202421:05GlobeNewswire Inc.4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
01/05/202413:00GlobeNewswire Inc.4DMT Announces Presentations at ARVO 2024 Annual MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
28/03/202412:00GlobeNewswire Inc.4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisNASDAQ:FDMT4D Molecular Therapeutics Inc
04/03/202413:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202422:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202421:05GlobeNewswire Inc.4DMT Reports Full Year 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
21/02/202422:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
15/02/202401:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
14/02/202421:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
14/02/202413:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
13/02/202402:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
13/02/202401:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
12/02/202413:00GlobeNewswire Inc.4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024NASDAQ:FDMT4D Molecular Therapeutics Inc
09/02/202421:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202421:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202421:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202421:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202401:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FDMT

Your Recent History

BIT
P21AN2
NLBNPIT21AN2 20240621 3.6
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved